[go: up one dir, main page]

CA2477701A1 - Formes posologiques a liberation controlee - Google Patents

Formes posologiques a liberation controlee Download PDF

Info

Publication number
CA2477701A1
CA2477701A1 CA002477701A CA2477701A CA2477701A1 CA 2477701 A1 CA2477701 A1 CA 2477701A1 CA 002477701 A CA002477701 A CA 002477701A CA 2477701 A CA2477701 A CA 2477701A CA 2477701 A1 CA2477701 A1 CA 2477701A1
Authority
CA
Canada
Prior art keywords
dosage form
core tablet
release
annular body
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002477701A
Other languages
English (en)
Inventor
E. Itzhak Lerner
Vered Rosenberger
Ofer Aqua
Moshe Flashner-Barak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2477701A1 publication Critical patent/CA2477701A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une forme posologique pharmaceutique à libération d'ordre zéro pour une administration orale à un patient. Cette forme comprend un micro comprimé enveloppé dans un corps annulaire de poudre comprimée ou de matériau granulaire. Un mode de réalisation préféré de la forme posologique pharmaceutique à libération d'ordre zéro consiste en une forme posologique pharmaceutique solide qui réduit le contact de l'ingrédient actif sous forme solide avec la muqueuse qui recouvre le tractus gastro-intestinal, ce qui présente un réel avantage dans l'administration d'un médicament anti-ulcéreux. L'invention concerne aussi un procédé de fabrication de la forme posologique à libération d'ordre zéro.
CA002477701A 2002-03-04 2003-03-03 Formes posologiques a liberation controlee Abandoned CA2477701A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36182102P 2002-03-04 2002-03-04
US60/361,821 2002-03-04
US29161902A 2002-11-12 2002-11-12
US10/291,619 2002-11-12
PCT/US2003/006591 WO2003075893A1 (fr) 2002-03-04 2003-03-03 Formes posologiques a liberation controlee

Publications (1)

Publication Number Publication Date
CA2477701A1 true CA2477701A1 (fr) 2003-09-18

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002477701A Abandoned CA2477701A1 (fr) 2002-03-04 2003-03-03 Formes posologiques a liberation controlee

Country Status (13)

Country Link
EP (1) EP1492508A4 (fr)
JP (1) JP2005524670A (fr)
KR (1) KR20100049695A (fr)
CN (1) CN1649569B (fr)
AU (2) AU2003217909C1 (fr)
BR (1) BR0308305A (fr)
CA (1) CA2477701A1 (fr)
EA (1) EA005866B1 (fr)
IL (1) IL163887A0 (fr)
MX (1) MXPA04008536A (fr)
NO (1) NO20044188L (fr)
NZ (1) NZ535083A (fr)
WO (1) WO2003075893A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
RU2005104827A (ru) * 2002-07-19 2006-07-27 Рэнбакси Лабораториз Лимитед (In) Таблетки суматриптана с замаскированным вкусом и способы их получения
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2003287488B8 (en) * 2002-11-12 2007-05-17 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
JP4693628B2 (ja) * 2003-11-14 2011-06-01 株式会社三和化学研究所 有核成型品の製造方法
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
CA2555406A1 (fr) * 2004-02-19 2005-09-01 Teva Pharmaceutical Industries, Ltd. Therapie amelioree utilisant une combinaison de raloxifene et d'alendronate
KR100701409B1 (ko) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 호박산 수마트립탄을 함유하는 약제학적 조성물
JP2012500221A (ja) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物
CN110368371A (zh) * 2014-04-08 2019-10-25 越洋医药开发(广州)有限公司 一种新型控释片
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
CN110604724A (zh) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 一种肠溶美沙拉秦缓释片剂及其制备方法
PE20251521A1 (es) * 2022-10-13 2025-06-05 Clarke Mosquito Control Products Inc Composiciones de tabletas insecticidas
JP2024083720A (ja) * 2022-12-12 2024-06-24 パナソニックＩｐマネジメント株式会社 水処理用徐放性固形薬剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
JPS61243016A (ja) * 1985-04-19 1986-10-29 Katsumi Takada 柱状の有効成分含有部分をもつ錠剤
GB8514666D0 (en) * 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
JPS6253918A (ja) * 1985-09-02 1987-03-09 Katsumi Takada 柱状の有効成分含有部分を埋没させた錠剤
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
JP3962108B2 (ja) * 1995-04-03 2007-08-22 中外製薬株式会社 スクラルファート含有製剤組成物
CA2184316A1 (fr) * 1995-09-12 1997-03-13 Wei-Chi Liao Systeme d'administration buccale pour agents therapeutiques
ES2173372T3 (es) * 1997-12-19 2002-10-16 Merck Patent Gmbh Comprimidos multicapa que contienen microorganismos probioticos, como por ejemplo latobacilos o bifidobacterias.
BR9813728A (pt) * 1997-12-22 2000-10-10 Schering Corp Composição de dispersão molecular com elevada biodisponibilidade
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
EP1377284B1 (fr) * 2000-06-28 2008-12-17 Palmetto Pharmaceuticals, LLC Formulations d'arginine liberation lente
EP2172192A1 (fr) * 2001-12-24 2010-04-07 Teva Pharmaceutical Industries Ltd. Forme de dosage dotée d'un comprimé central d'ingrédient actif insérée dans un corps annulaire comprimé de poudre de matériau granulaire et procédé et outillage pour la produire

Also Published As

Publication number Publication date
NO20044188L (no) 2004-12-03
AU2003217909B2 (en) 2008-10-30
JP2005524670A (ja) 2005-08-18
EP1492508A4 (fr) 2009-05-06
NZ535083A (en) 2007-06-29
AU2003217909C1 (en) 2009-06-11
AU2009200353A1 (en) 2009-02-19
AU2003217909A1 (en) 2003-09-22
IL163887A0 (en) 2005-12-18
KR20100049695A (ko) 2010-05-12
CN1649569A (zh) 2005-08-03
BR0308305A (pt) 2004-12-28
CN1649569B (zh) 2010-05-05
EA200401097A1 (ru) 2005-04-28
EA005866B1 (ru) 2005-06-30
MXPA04008536A (es) 2005-09-08
WO2003075893A1 (fr) 2003-09-18
EP1492508A1 (fr) 2005-01-05

Similar Documents

Publication Publication Date Title
US20040052843A1 (en) Controlled release dosage forms
JP4414228B2 (ja) 活性成分の芯錠剤が粉末または顆粒状材料の圧縮環状体の鞘に収められた剤形とその製造方法および器具類
AU2009200353A1 (en) Controlled release dosage forms
AU736052B2 (en) Pharmaceutical compositions for controlled release of active substances
US20060153918A1 (en) Dosage forms with an enterically coated core tablet
ZA200407023B (en) Controlled release dosage forms
AU2002352613B2 (en) Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
KR20050023235A (ko) 방출 조절 투여 형태
ZA200405012B (en) Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of power or granular material, and process and tooling for producing it.
CN101888833A (zh) 包含肠溶衣包被的芯片的剂型

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued